Valuation: SI-BONE, Inc.

Capitalization 611M 527M 475M 456M 832M 56.13B 871M 5.62B 2.25B 26.92B 2.29B 2.24B 96.27B P/E ratio 2026 *
-27.2x
P/E ratio 2027 * -35.5x
Enterprise value 497M 428M 387M 371M 676M 45.65B 708M 4.57B 1.83B 21.89B 1.86B 1.82B 78.3B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 1.85x
Free-Float
97.68%
Yield 2026 *
-
Yield 2027 * -
1 day-1.71%
1 week-10.89%
Current month-10.89%
1 month-11.29%
3 months-29.73%
6 months-15.10%
Current year-29.87%
1 week 13.69
Extreme 13.691
15.74
1 month 13.69
Extreme 13.691
16.88
Current year 13.69
Extreme 13.691
21.89
1 year 12.5
Extreme 12.495
21.89
3 years 11.7
Extreme 11.7
29.51
5 years 11.14
Extreme 11.14
37.21
10 years 7.2
Extreme 7.2
37.21
Manager TitleAgeSince
Chief Executive Officer 59 19/04/2021
Director of Finance/CFO 46 18/04/2021
Chief Tech/Sci/R&D Officer - 31/05/2021
Director TitleAgeSince
Chairman 71 17/03/2008
Director/Board Member 79 31/12/2010
Director/Board Member 72 31/12/2012
Change 5d. change 1-year change 3-years change Capi.($)
-1.71%-10.89%-13.89%-34.67% 611M
-0.58%-1.67%+23.24%+33.00% 13.29B
-0.02%+0.04%+0.52%-0.92% 9.16B
-0.38%-3.50%-9.48%-11.12% 5.8B
+2.62%-2.14%+33.36%+39.75% 5.54B
+1.74%-4.65%+0.03%+13.85% 5.34B
-2.94%0.00% - - 5.19B
+1.54%-6.23%-9.26%+37.50% 4.72B
+2.82%-2.83%+5.88%-54.63% 1.7B
-8.36%-4.61%-35.38%-82.59% 1.48B
Average -0.53%-2.98%-0.55%-6.65% 5.28B
Weighted average by Cap. -0.06%-1.87%+7.32%+12.60%

Financials

2026 *2027 *
Net sales 230M 199M 179M 172M 314M 21.17B 328M 2.12B 849M 10.15B 865M 846M 36.31B 265M 228M 206M 198M 361M 24.33B 377M 2.44B 976M 11.67B 994M 973M 41.73B
Net income -22.88M -19.73M -17.81M -17.09M -31.16M -2.1B -32.61M -210M -84.33M -1.01B -85.86M -84.03M -3.61B -17.69M -15.25M -13.77M -13.21M -24.09M -1.63B -25.21M -163M -65.2M -780M -66.38M -64.97M -2.79B
Net Debt -114M -98.34M -88.77M -85.18M -155M -10.48B -163M -1.05B -420M -5.03B -428M -419M -17.98B -121M -104M -94.01M -90.2M -164M -11.1B -172M -1.11B -445M -5.32B -453M -444M -19.04B
Logo SI-BONE, Inc.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Employees
376
Date Price Change Volume
06/03/26 13.83 $ -1.71% 532,012
05/03/26 14.07 $ -4.35% 755,037
04/03/26 14.71 $ -4.11% 419,226
03/03/26 15.34 $ -2.29% 426,038
02/03/26 15.70 $ +1.16% 754,364
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.83USD
Average target price
25.67USD
Spread / Average Target
+85.59%

Quarterly revenue - Rate of surprise